CN117693348A - 靶向uPAR的抗原识别受体和其用途 - Google Patents

靶向uPAR的抗原识别受体和其用途 Download PDF

Info

Publication number
CN117693348A
CN117693348A CN202280051477.5A CN202280051477A CN117693348A CN 117693348 A CN117693348 A CN 117693348A CN 202280051477 A CN202280051477 A CN 202280051477A CN 117693348 A CN117693348 A CN 117693348A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280051477.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·W·洛
M·塞德莱恩
C·阿莫尔维加斯
张则达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer And Related Diseases Memorial Hospital
Sloan Caitlin Cancer Research Association
Memorial Sloan Kettering Cancer Center
Original Assignee
Cancer And Related Diseases Memorial Hospital
Sloan Caitlin Cancer Research Association
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer And Related Diseases Memorial Hospital, Sloan Caitlin Cancer Research Association, Memorial Sloan Kettering Cancer Center filed Critical Cancer And Related Diseases Memorial Hospital
Publication of CN117693348A publication Critical patent/CN117693348A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202280051477.5A 2021-06-11 2022-06-10 靶向uPAR的抗原识别受体和其用途 Pending CN117693348A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209940P 2021-06-11 2021-06-11
US63/209,940 2021-06-11
PCT/US2022/032954 WO2022261403A1 (en) 2021-06-11 2022-06-10 Antigen recognizing receptors targeting upar and uses thereof

Publications (1)

Publication Number Publication Date
CN117693348A true CN117693348A (zh) 2024-03-12

Family

ID=84425517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280051477.5A Pending CN117693348A (zh) 2021-06-11 2022-06-10 靶向uPAR的抗原识别受体和其用途

Country Status (7)

Country Link
US (1) US20240123069A1 (enExample)
EP (1) EP4351602A4 (enExample)
JP (1) JP2024520803A (enExample)
CN (1) CN117693348A (enExample)
AU (1) AU2022287930A1 (enExample)
CA (1) CA3221368A1 (enExample)
WO (1) WO2022261403A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189685A1 (zh) * 2024-03-15 2025-09-18 臻赫医药(杭州)有限公司 一种嵌合抗原受体纳米复合物及其制备方法和在制备抗衰老药物中的应用
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221342A1 (en) * 2021-06-11 2022-12-15 Scott W. Lowe Antigen recognizing receptors targeting upar and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100620A2 (en) * 2010-02-12 2011-08-18 The Regents Of The University Of California Upar binding agents and methods of use thereof
AU2012293720A1 (en) * 2011-08-05 2014-02-27 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies
EP3283522A1 (en) * 2015-04-17 2018-02-21 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US20220098320A1 (en) * 2019-02-01 2022-03-31 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
CN110343665B (zh) * 2019-05-05 2023-07-14 吉林大学 一种car-t细胞及其应用
CA3215364A1 (en) * 2021-04-13 2022-10-20 Scott W. Lowe Car-t cells targeting upar and uses thereof
CA3221342A1 (en) * 2021-06-11 2022-12-15 Scott W. Lowe Antigen recognizing receptors targeting upar and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189685A1 (zh) * 2024-03-15 2025-09-18 臻赫医药(杭州)有限公司 一种嵌合抗原受体纳米复合物及其制备方法和在制备抗衰老药物中的应用
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
JP2024520803A (ja) 2024-05-24
EP4351602A4 (en) 2025-07-30
AU2022287930A9 (en) 2024-01-11
US20240123069A1 (en) 2024-04-18
CA3221368A1 (en) 2022-12-15
AU2022287930A1 (en) 2023-12-14
WO2022261403A1 (en) 2022-12-15
EP4351602A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
US12005081B2 (en) Chimeric receptors and methods of use thereof
JP2022105192A (ja) Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
JP6919091B2 (ja) Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
US20210393689A1 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
JP7174522B2 (ja) Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
CA3128368A1 (en) Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
CA3114788A1 (en) Immunoresponsive cells expressing dominant negative fas and uses thereof
CN113454115B (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
US20240123069A1 (en) Antigen recognizing receptors targeting upar and uses thereof
AU2018367449B2 (en) IL-33 secreting immunoresponsive cells and uses thereof
US20240131070A1 (en) Antigen recognizing receptors targeting upar and uses thereof
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
JP2024516713A (ja) キメラ受容体およびその使用方法
EP4458956A1 (en) Anti-mesothelin nanobody chimeric antigen receptor and use thereof
WO2025193972A1 (en) Methods of using il-15 signaling to enhance nk and nk-like t cell function against aml
EP4724076A2 (en) Systems and methods to direct cellular therapies in vivo to an organ
HK40128378A (zh) 对δ样配体3(DLL3)具有特异性的抗体和嵌合抗原受体
WO2024050551A2 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
WO2025085796A1 (en) Armored immunoresponsive cells targeting dll3 and uses thereof
CN118369332A (zh) 靶向cd33的抗原识别受体和其用途
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia
BR112017011909B1 (pt) Receptor de antígeno quimérico (car), molécula de ácido nucleico, vetor, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar um tumor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination